Eli Lilly and Company (LLY) Covered Calls

Eli Lilly and Company covered calls Eli Lilly and Company is a global pharmaceutical leader focused on discovering and developing innovative medicines in the areas of oncology, immunology, neuroscience, and endocrinology. The company is widely recognized for its pioneering work in diabetes care and its recent breakthroughs in obesity management. By leveraging advanced biotechnology and research, Lilly aims to provide high-quality treatments that improve patient outcomes and address some of the world’s most challenging diseases.

You can sell covered calls on Eli Lilly and Company to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for LLY (prices last updated Wed 4:16 PM ET):

Eli Lilly and Company (LLY) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1,107.12 +103.66 1,105.50 1,107.00 7.1M 49 949
Covered Calls For Eli Lilly and Company (LLY)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 1105 32.10 1074.90 3.0% 64.4%
Mar 20 1110 50.10 1056.90 4.9% 39.7%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Core Business and Products

Eli Lilly and Company is a world-renowned leader in the healthcare sector, specializing in the development of branded pharmaceutical products. With a heritage spanning over 150 years, the company has transformed from a small family business into a global innovation powerhouse. Its current business strategy is heavily centered on "biomedical breakthroughs" that address significant unmet medical needs.

  1. Endocrinology and Metabolic Health: This is the company's most prominent segment. Key products include Mounjaro (for type 2 diabetes) and Zepbound (for weight management). These drugs utilize tirzepatide, a dual GIP and GLP-1 receptor agonist. Other critical products in this space include Jardiance and the Trulicity franchise.
  2. Oncology: Lilly has a robust cancer treatment portfolio, led by Verzenio, which is used for certain types of breast cancer. The company also develops targeted therapies like Jaypirca for mantle cell lymphoma.
  3. Neuroscience: Building on its legacy with drugs like Prozac, Lilly is currently a pioneer in Alzheimer’s research with Kisunla (donanemab). It also maintains a presence in migraine treatment with Emgality.
  4. Immunology: This segment features Taltz, used for plaque psoriasis and psoriatic arthritis, and Olumiant, which treats rheumatoid arthritis and alopecia areata.

Competitive Landscape

Lilly operates in a highly regulated and research-intensive environment, competing with other "Big Pharma" giants and biotechnology firms for market share and patent dominance:

  1. Metabolic Rivalry: Lilly's primary competitor in the lucrative diabetes and obesity market is Novo Nordisk. While Novo Nordisk is a major rival, it is a Danish company; however, its ADRs trade on a major domestic exchange. Other emerging competitors in the weight-loss pill space include Viking Therapeutics and Amgen.
  2. General Oncology and Immunology: In these broad categories, Lilly competes with diversified peers such as AbbVie, Pfizer, Merck, and Bristol Myers Squibb.
  3. Specialized Biotech: For specific indications like Alzheimer’s, Lilly rivals Biogen.

Strategic Outlook and Innovation

As of 2026, Eli Lilly is in a massive expansion phase, investing billions of dollars into its "Foundry" manufacturing sites in Indiana and Ireland to meet the global surge in demand for its injectable and upcoming oral metabolic treatments. The company is also at the forefront of integrating artificial intelligence into drug discovery. In partnership with NVIDIA, Lilly is utilizing supercomputing to accelerate clinical trial design and protein folding simulations. This "AI-first" approach to R&D is designed to shorten the traditional ten-year drug development cycle, ensuring a steady pipeline of next-generation therapies for immunology and rare diseases.